01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech companies...
17:34 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN) have proposed to list on NASDAQ. Alector, which aims to target immune dysfunction to treat neurodegenerative disorders,...
04:39 , Jan 8, 2019 |  BC Extra  |  Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN) have proposed to list on NASDAQ. Alector, which aims to target immune dysfunction to treat neurodegenerative disorders,...
23:44 , Nov 19, 2018 |  BC Extra  |  Company News

Management tracks: Brickell, Genevant

Dermatology company Brickell Biotech Inc. (Boulder, Colo.) hired Robert Brown as CEO, effective Jan. 1. He will replace co-founder and CEO Reginald Hardy, who will remain on the board and serve as special adviser to...
18:29 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Biomatics closes second fund at $300M

Biomatics Capital Partners closed its second fund at $300 million and added Mike Poole and Errik Anderson as venture partners (see "Biomatics' Next Phase" ). Fund II will invest in 15-20 healthcare companies across therapeutics,...
00:10 , Nov 9, 2018 |  BioCentury  |  Finance

Biomatics’ next phase

Biomatics Capital plans to take a more active role in company formation and seek more neuroscience investments with its second fund, and has brought on two partners to implement its strategy. With Fund II, which...
13:02 , Nov 8, 2018 |  BC Extra  |  Financial News

Biomatics closes new fund at $300M

Biomatics Capital Partners closed its second fund at $300 million and added Mike Poole and Errik Anderson as venture partners (see "Biomatics' Next Phase" ). Fund II will invest in 15-20 healthcare companies across therapeutics,...
16:39 , Oct 26, 2018 |  BC Week In Review  |  Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

The Dementia Discovery Fund (DDF) and UK Dementia Research Institute launched a partnership dubbed D3A to grant multiple awards of £100,000-£200,000 ($130,768-$261,536) to support clinical translation. D3A will fund translational projects from UK Dementia Research...
17:18 , Oct 24, 2018 |  BC Extra  |  Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

The Dementia Discovery Fund (DDF) and UK Dementia Research Institute launched a partnership dubbed D3A to grant multiple awards of £100,000-£200,000 ($130,768-$261,536) to support clinical translation. D3A will fund translational projects from UK Dementia Research...
19:59 , Jul 27, 2018 |  BioCentury  |  Finance

Manipulating microglia

Alector Inc.’s $133 million series E round provides enough runway for the immuno-neurology and immuno-oncology company to take at least five programs into the clinic in the next two years. Participants in the untranched round,...